Nigeria on Wednesday launched its first clinical trial using immunotherapy to treat colorectal cancer, a move doctors say could expand options for patients who do not respond to conventional chemotherapy.
The Phase II study will test a PD-1 blocking drug in patients whose tumours carry a genetic
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
Royal Ibeh
Royal Ibeh is a senior journalist with years of experience reporting on Nigeria’s technology and health sectors. She currently covers the Technology and Health beats for BusinessDay newspaper, where she writes in-depth stories on digital innovation, telecom infrastructure, healthcare systems, and public health policies.
